Payment overview · 2025
General Payments
$585.50
31 reported records · 17 companies
Healthcare provider profile · identity verified
Tamara Barsik, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALLEN, TX · NPI 1356320378
Verified facts
What the public records show
CMS Open Payments records show Tamara Barsik, MD received $585.50 in general payments during 2025 across 31 reported records.
Corcept Therapeutics accounted for 13.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $80.05 | 13.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.23 | 12.0% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $67.47 | 11.5% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $53.97 | 9.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.07 | 8.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.04 | 6.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.54 | 5.4% | 2 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $29.27 | 5.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.54 | 4.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.44 | 4.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.71 | 3.2% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.55 | 3.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.68 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.89 | 2.7% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $14.85 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.68 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.52 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $585.50 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $80.05 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $67.47 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.20 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $53.97 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $50.25 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.07 | 2 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $29.27 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $29.27 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.54 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 986 | 159 |
| Atorvastatin Calcium | Atorvastatin Calcium | 820 | 191 |
| Gabapentin | Gabapentin | 748 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 623 | 146 |
| Losartan Potassium | Losartan Potassium | 514 | 117 |
| Metformin Hcl | Metformin Hcl | 486 | 100 |
| Furosemide | Furosemide | 430 | 99 |
| Lisinopril | Lisinopril | 422 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 396 | 85 |
| Trazodone Hcl | Trazodone Hcl | 342 | 64 |
| Eliquis | Apixaban | 337 | 53 |
| Potassium Chloride | Potassium Chloride | 337 | 73 |
| Carvedilol | Carvedilol | 314 | 58 |
| Donepezil Hcl | Donepezil Hcl | 303 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 286 | 70 |
| Divalproex Sodium | Divalproex Sodium | 271 | 25 |
| Sertraline Hcl | Sertraline Hcl | 249 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 52 |
| Gemtesa | Vibegron | 234 | 14 |
| Mirtazapine | Mirtazapine | 232 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 217 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 216 | 49 |
| Risperidone | Risperidone | 200 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 74 |
| Hydralazine Hcl | Hydralazine Hcl | 193 | 40 |
| Levetiracetam | Levetiracetam | 191 | 20 |
| Simvastatin | Simvastatin | 188 | 38 |
| Memantine Hcl | Memantine Hcl | 176 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 172 | 30 |
| Montelukast Sodium | Montelukast Sodium | 165 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 31 |
| Olanzapine | Olanzapine | 152 | 15 |
| Lorazepam | Lorazepam | 148 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 53 |
| Buspirone Hcl | Buspirone Hcl | 129 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 19 |
| Nifedipine Er | Nifedipine | 122 | 31 |
| Omeprazole | Omeprazole | 121 | 36 |
| Clonazepam | Clonazepam | 118 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 34 |
| Lamotrigine | Lamotrigine | 113 | suppressed |
| Famotidine | Famotidine | 112 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 106 | 16 |
| Propranolol Hcl | Propranolol Hcl | 105 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 27 |
| Baclofen | Baclofen | 101 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 100 | suppressed |
| Allopurinol | Allopurinol | 98 | 20 |
| Latanoprost | Latanoprost | 98 | 20 |
| Jardiance | Empagliflozin | 97 | 15 |
| Tramadol Hcl | Tramadol Hcl | 97 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 21 |
| Xarelto | Rivaroxaban | 88 | 11 |
| Januvia | Sitagliptin Phosphate | 84 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 84 | suppressed |
| Ezetimibe | Ezetimibe | 82 | 26 |
| Meloxicam | Meloxicam | 79 | 39 |
| Cefdinir | Cefdinir | 78 | 73 |
| Glipizide | Glipizide | 76 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 75 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 23 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 67 | suppressed |
| Azithromycin | Azithromycin | 65 | 59 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | suppressed |
| Klor-Con M20 | Potassium Chloride | 64 | 11 |
| Alendronate Sodium | Alendronate Sodium | 63 | 30 |
| Movantik | Naloxegol Oxalate | 63 | suppressed |
| Lactulose | Lactulose | 61 | 12 |
| Lovastatin | Lovastatin | 60 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 31 |
| Celecoxib | Celecoxib | 59 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 25 |
| Alprazolam | Alprazolam | 57 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 42 |
| Tradjenta | Linagliptin | 55 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | suppressed |
| Prednisone | Prednisone | 53 | 33 |
| Calcitriol | Calcitriol | 50 | suppressed |
| Ozempic | Semaglutide | 50 | 12 |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 49 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 24 |
| Spironolactone | Spironolactone | 47 | 12 |
| Finasteride | Finasteride | 46 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | 15 |
| Methocarbamol | Methocarbamol | 45 | 23 |
| Methylprednisolone | Methylprednisolone | 45 | 40 |
| Nystatin | Nystatin | 45 | 27 |
| Torsemide | Torsemide | 45 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 17 |
| Valsartan | Valsartan | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 38 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 37 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 12 |
| Bumetanide | Bumetanide | 36 | 12 |
| Digoxin | Digoxin | 36 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 15 |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 27 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 19 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 31 | suppressed |
| Humulin R | Insulin Regular, Human | 30 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 28 | 11 |
| Megestrol Acetate | Megestrol Acetate | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 12 |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Amantadine | Amantadine Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 25 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 24 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 20 |
| Brilinta | Ticagrelor | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Acetazolamide | Acetazolamide | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Budesonide | Budesonide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Exemestane | Exemestane | 18 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Rytary | Carbidopa/Levodopa | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Daptomycin | Daptomycin | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Olanzapine Odt | Olanzapine | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 12 |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nystop | Nystatin | 13 | 11 |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 11 |
| Diazepam | Diazepam | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $585.50 · 31 records | Corcept Therapeutics | CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, EVENITY, FLOWTRIEVER CATHETER, S, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, INSPIRE, KISUNLA, Kerendia, Korlym, Leqembi, Omnipod, Ozempic, PROLIA, REXULTI, TAVNEOS, TZIELD, VRAYLAR, XIFAXAN, ZENPEP | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error